Christopher Yea Net Worth & Insider Trades

Christopher Yea - Chief Development Officer, Kalvista Pharmaceuticals, Inc

As of August 19, 2022

What is Christopher Yea's Net Worth?

The current estimated net worth of Kalvista Pharmaceuticals, Inc's Chief Development Officer, Christopher Yea, is estimated to be about $2.5M . Christopher Yea owns about 33,597 units of Kalvista Pharmaceuticals, Inc common stock. In the last 6 years at Kalvista Pharmaceuticals, Inc, Christopher Yea has sold an estimated value of $1.77M worth.

What is Christopher Yea's Past Insider Trading?

Christopher Yea's largest purchase order was 7,355 units , worth over $31.63 on July 24, 2019. Christopher Yea's largest sale order was 15,000 units , worth over $503.88K on February 25, 2021. In total, Christopher Yea has made about 24 transactions over 6 years of their time at Kalvista Pharmaceuticals, Inc. Christopher Yea usually trades in May, with the busiest year in 2019. The most recent transaction was a sale order of 1,145 units , worth over $17.13K on August 19, 2022.

Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

What was Christopher Yea's Salary in 2021?

As Chief Development Officer of Kalvista Pharmaceuticals, Inc, Christopher Yea has a total base salary of $420,000 . Christopher Yea received compensation valued at about $1,409,401 in 2021 after becoming Chief Development Officer. The vast majority of their compensation came in the form of a bonus of $252,000 , option awards of $712,060 , and other compensation of $25,341 .

What is Christopher Yea's' Mailing Address?

  • Mailing address is One Kendall Square, Building 200 Suite 2203 Cambridge MA 02139 MA

Kalvista Pharmaceuticals, Inc Executive Compensation

Name
Year
Salary
Bonus
Stock Awards
Option Awards
Other Compensation
Total
T. Andrew Crockett 2021 $556,120 $458,799 - $1,281,708 $11,400 $2,308,027
T. Andrew Crockett 2020 $556,120 $229,400 - $1,163,160 $11,882 $1,960,562
T. Andrew Crockett 2019 $505,000 $353,500 - $2,418,444 $11,000 $3,287,944
Benjamin L. Palleiko 2021 $435,000 $261,000 - $747,663 $15,850 $1,459,513
Benjamin L. Palleiko 2020 $435,000 $156,600 - $581,580 $11,900 $1,185,080
Benjamin L. Palleiko 2019 $366,000 $192,150 $527,794 $994,555 $11,000 $2,091,499
Christopher M. Yea 2021 $420,000 $252,000 - $712,060 $25,341 $1,409,401
Christopher M. Yea 2020 $420,000 $117,600 - $480,773 $25,271 $1,094,044
Christopher M. Yea 2019 $341,093 $174,596 - $891,350 $20,466 $1,427,505
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1348911/000119312521249158/d191826ddef14a.htm

What are Kalvista Pharmaceuticals, Inc's Past Insider Trades?

Kalvista Pharmaceuticals, Inc's most recent insider trade came on September 7, 2022 by Andrew Thomas Crockett who sold 7,820 units worth $22.46K . In the last 5 years, insiders at Kalvista Pharmaceuticals, Inc have sold an estimated value of $75.63M and bought an estimated value of $44.2M worth of shares. Insider trading is most common in October, with the busiest year in 2019 and 2021. The most active traders at the company are Andrew Thomas Crockett, CEO,  Christopher Yea, Chief Development Officer,  and Edward Feener, Chief Scientific Officer .

KalVista Pharmaceuticals, Inc. Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1